Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 14;17:89. doi: 10.1186/s12933-018-0732-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 6 — No effect of diabetes or CaMKIIδ inhibition with KN93 on Ca²⁺ transient properties. a, b Representative confocal line scan images (upper) and normalized Ca²⁺ transients (lower) from non-diabetic (nDM) and diabetic (DM) cardiomyocytes in the presence of KN92 and KN93. c Mean Ca²⁺ transient amplitude (F/F0, where F0 is diastolic fluorescence). d Mean time constant of Ca²⁺ decay (Tau). e, f Representative confocal line scan images (upper) and normalized Ca²⁺ transients (lower) from nDM to diabetic (DM) cardiomyocytes in the presence of CTRL and AIP. g Mean Ca²⁺ transient amplitude. h Mean time constant of Ca²⁺ decay (Tau). Data are mean ± SEM. n = 13–17 cells. For all parameters two-way between groups ANOVA: treatment effect *p < 0.05